Current concepts and controversies in the management of early stage Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 962-971

  Maeda, Lauren S ^a   Lee, Mark ^a   Advani, Ranjana H ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lymphoma and Hodgkin disease; pharmacotherapeutics; prognostication

Indexed keywords

BIOLOGICAL MARKER; BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CLINICAL TRIAL (TOPIC); EUROPE; HODGKIN DISEASE; HUMAN; NORTH AMERICA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; TREATMENT DURATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; EUROPE; HODGKIN DISEASE; HUMANS; NEOPLASM STAGING; NORTH AMERICA; PROGNOSIS; RADIOTHERAPY;

EID: 79957495891     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.557455     Document Type: Review

References (54)

1. Armitage JO. Early-stage Hodgkins lymphoma. N Engl J Med 2010;363:653-662.
2. Gospodarowicz MK, Sutcliffe SB, Bergsagel DE, Chua T. Radiation therapy in clinical stage I and II Hodgkins disease. Eur J Cancer 1992;28:1841-1846.
3. Duhmke E, Diehl V, Loeffler M, et al. Randomized trial with early-stage Hodgkins disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 1996;36:305-310. (Pubitemid 26359453)
4. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkins lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007;25:3495-3502. (Pubitemid 47310889)
5. Press OW, LeBlanc M, Lichter AS, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkins disease. J Clin Oncol 2001;19:4238-4244. (Pubitemid 33081641)
6. Horning SJ, Hoppe RT, Hancock SL, Rosenberg SA. Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkins disease. J Clin Oncol 1988;6: 1822-1831. (Pubitemid 19089064)
7. Horning SJ, Hoppe RT, Mason J, et al. Stanford-Kaiser Permanente G1 study for clinical stage I to IIA Hodgkins disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997;15:1736-1744. (Pubitemid 27209499)
8. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkins lymphoma: longterm results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128-3135. (Pubitemid 46638951)
9. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkins disease. N Engl J Med 2007;357:1916-1927. (Pubitemid 350074687)
10. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkins lymphoma: results of the HD8 trial of the German Hodgkins Lymphoma Study Group. J Clin Oncol 2003;21:3601-3608. (Pubitemid 46594052)
11. Noordijk EM, Carde P, Mandard AM, et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkins disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann Oncol 1994;5(Suppl. 2):107-112. (Pubitemid 24061330)
12. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkins disease: long-term results. J Clin Oncol 2004;22:2835-2841. (Pubitemid 41079901)
13. Ferme C, Divine M, Vranovsky A, et al. Four ABVD and involved-field radiotherapy in unfavorable supradiaphragmatic clinical stages (CS) I-II Hodgkins lymphoma (HL): preliminary results of the EORTC-GELA H9-U trial. Blood 2005;106(Suppl. 1): Abstract 813.
14. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkins lymphoma. N Engl J Med 2010;363:640-652.
15. Borchmann P, Diehl V, Goergen H, et al. Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin lymphoma (HL): final analysis of the German Hodgkin Study Group (GHSG) HD11 Trial. Blood 2009; 114(Suppl. 1): Abstract 717.
16. Borchmann P, Engert A, Pluetschow A, et al. Dose-intensified combined modality treatment with 2 cycles of BEACOPP escalated followed by 2 cycles of ABVD and involved field radiotherapy (IF-RT) is superior to 4 cycles ofABVDand IFRT in patients with early unfavourable Hodgkin lymphoma (HL): an analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood 2008;112(Suppl. 1): Abstract 367.
17. Crnkovich MJ, Leopold K, Hoppe RT, Mauch PM. Stage I to IIB Hodgkins disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 1987;5:1041-1049. (Pubitemid 18056010)
18. Fuller LM, Madoc-Jones H, Hagemeister FB Jr, et al. Further follow-up of results of treatment in 90 laparotomy-negative stage I and II Hodgkins disease patients: significance of mediastinal and non-mediastinal presentations. Int J Radiat Oncol Biol Phys 1980;6:799-808. (Pubitemid 10015028)
19. Schomberg PJ, Evans RG, OConnell MJ, et al. Prognostic significance of mediastinal mass in adult Hodgkins disease. Cancer 1984;53:324-328. (Pubitemid 14180750)
20. Advani RH, Hoppe RT, Maeda LS, et al. Stage I-IIA nonbulky Hodgkin lymphoma: is further distinction based on prognostic factors useful? The Stanford experience. Int J Radiat Oncol Biol Phys 2010 Oct 7. [Epub ahead of print]
21. Sieniawski M, Franklin J, Nogova L, et al. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkins lymphoma. J Clin Oncol 2007;25:2000-2005. (Pubitemid 46972783)
22. Radford JA, Cowan RA, Ryder WDJ. Four weeks of neoadjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical stage (CS) IA/IIA Hodgkins disease. Results of a randomised pilot study. Leuk Lymphoma 1998;29(Suppl.): Abstract O-5.
23. Advani RH, Hoppe RT, Baer DM, Mason J, Rosenberg SA, Horning SJ. Efficacy of abbreviated Stanford V chemotherapy and involved field radiotherapy in early stage Hodgkins disease: mature results of the G4 trial. Blood 2009;114(Suppl. 1): Abstract 1670.
24. Noordijk EM, Thomas J, Ferme C, et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkins lymphoma (HL). J Clin Oncol 2005;23(16S Suppl.): Abstract 6505.
25. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkins lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-4642. (Pubitemid 46237440)
26. Macdonald DA, Ding K, Gospodarowicz MK, et al. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma. Ann Oncol 2007;18:1680-1684. (Pubitemid 47506255)
27. Straus D, LaCase A, JuweidM, et al. Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin lymphoma (HL): results of CALGB 50203. Blood 2007;110(Suppl. 1): Abstract 214.
28. Herbst C, Rehan FA, Brillant C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkins lymphoma: a systematic review. Haematologica 2010;95:494-500.
29. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Hodgkin Lymphoma v.2.2010 [Internet]. National Comprehensive Cancer Network, Inc. July 2010. Available from: http://www.nccn.org/professionals/ physician-gls/f-guidelines.asp
30. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkins lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009;27:4548-4554.
31. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkins lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:4199-4206.
32. Engert A, Borchmann P, Pluetschow A, et al. Dose-escalation with BEACOPP escalated is superior to ABVD in the combined-modality treatment of early unfavorable Hodgkin lymphoma: final analysis of the German Hodgkin Study Group (GHSG) HD14 trial. Blood 2010;116(Suppl. 1): Abstract 765.
33. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkins disease: mature results of a prospective clinical trial. J Clin Oncol 2002;20:630-637. (Pubitemid 34111368)
34. Advani RH, Hoppe RT, Rosenberg SA, Horning SJ. Stage I/II Hodgkins disease: comparison of outcomes of patients with bulky mediastinal disease versus other risk factors; the Stanford V experience. Blood 2007;110(Suppl. 1): Abstract 2316.
35. Edwards-Bennett SM, Jacks LM, Moskowitz CH, et al. Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience. Ann Oncol 2010;21:574-581.
36. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkins lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009;27: 5390-5396.
37. Aleman BM, van den Belt-Dusebout AW, De BruinML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-1886. (Pubitemid 46348183)
38. Gordon LI, Hong F, Fisher RI, et al. A randomized phase III trial of ABVD vs. Stanford V /7 radiation therapy in locally extensive and advanced stage Hodgkins lymphoma: an intergroup study coordinated by the Eastern Cooperatve Oncology Group (E2496). Blood 2010;116(Suppl. 1): Abstract 415.
39. Advani R, Hong F, Fisher RI, et al. Randomized phase III trial comparing ABVD radiotherapy and the Stanford V regimen in patients with stage I/II bulky mediastinal Hodgkin lymphoma: a subset analysis of the US intergroup trial E2496. Blood 2010;116(Suppl. 1): Abstract 416.
40. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2- [18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkins lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007;25:3746-3752. (Pubitemid 47372616)
41. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160-1168. (Pubitemid 41418320)
42. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression- free survival in Hodgkin lymphoma. Blood 2006;107: 52-59. (Pubitemid 43053523)
43. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkins disease patients. Ann Oncol 2006;17:1296-1300. (Pubitemid 44288221)
44. Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkins lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007;48:1721-1727. (Pubitemid 47386707)
45. Savage KJ, Connors JM, Wilson D, et al. FDG-PET guided consolidative radiotherapy in patients with advanced stage Hodgkin lymphoma with residual abnormalities on post chemotherapy CT scan. Blood 2007;110(Suppl. 1): Abstract 213.
46. Weber DC, Peguret N, Dipasquale G, Cozzi L. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 2009;75:1578-1586.
47. Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkins lymphoma: a question of field size. J Clin Oncol 2008;26:5170-5174.
48. Andre MP, Reman O, Federico M, et al. First report on the H10 EORTC/GELA/IIL randomized intergroup trial on early FDG-PET scan guided treatment adaptation versus standard combined modality treatment in patients with supra-diaphragmatic stage I/II Hodgkins lymphoma, for the Groupe dEtude Des Lymphomes De lAdulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL). Blood 2009;114(Suppl. 1): Abstract 97.
49. Lee AI, Zuckerman DS, Van den Abbeele AD, et al. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer 2010;116: 3835-3842.
50. Maeda LS, Horning SJ, Iagaru AH, et al. Role of FDG-PET/ CT surveillance for patients with classical Hodgkins disease in first complete response: the Stanford University experience. Blood 2009;114(Suppl. 1): Abstract 1563.
51. Basciano BA, Moskowitz C, Zelenetz AD. et al. Impact of routine surveillance imaging on the outcome of patients with relapsed Hodgkin lymphoma. Blood 2009;114(Suppl. 1): Abstract 1558.
52. Hsi ED. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment. Leuk Lymphoma 2008;49:1668-1680.
53. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, et al. BCL- 2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002;100: 3935-3941. (Pubitemid 35396858)
54. Steidl C, Lee T, Shah SP, et al. Tumor-associated macrophages and survival in classic Hodgkins lymphoma. N Engl J Med 2010;362:875-885.